Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04112641 · ClinicalTrials.gov registry record · Phase 2
NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy
A Phase 2 study of Chemotherapy-induced Peripheral Neuropathy, sponsored by Donna Hammond, PhD.
- Active
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT04112641: Active Phase 2 study of Chemotherapy-induced Peripheral Neuropathy, sponsored by Donna Hammond, PhD.
NCT04112641 is a Phase 2 study of Chemotherapy-induced Peripheral Neuropathy that is active but no longer recruiting, run by Donna Hammond, PhD. The registered enrollment target is 48 participants, below the 137-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04112641, a Phase 2 study of Chemotherapy-induced Peripheral Neuropathy, is active but no longer recruiting, sponsored by Donna Hammond, PhD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this randomized, double-blind, placebo-controlled, parallel group phase II trial is to determine whether nicotinamide riboside (NIAGEN®, NR) can ameliorate persistent peripheral neuropathy in cancer survivors who have completed chemotherapy with taxane or platinum-complex compounds between 1 and 12 months earlier.
Primary Outcome
Change in score from baseline to end of treatment at 84 days. The Quality of Life Questionnaire for Chemotherapy-induced Peripheral Neuropathy (20 questions) or QLQ-CIPN20 yields scores of 1-4 (Likert scale) for 9 sensory, 8 motor, and 3 autonomic sequelae of chemotherapy. The minimum score for the sensory subscale is 9 and the maximum possible score is 36. The higher the score, the worse the signs and symptoms. The raw score can, at the investigator's discretion, be linearly transformed to a 0-
Conditions Studied
Interventions
- DRUG Placebo capsules
- DRUG Nicotinamide riboside
Study Locations (1)
Iowa
- Donna Hammond - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-02-19 |
| Est. Completion | 2026-07-01 |
| Phase | Phase 2 |
What the registry record for NCT04112641 still lists
NCT04112641 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 137-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Chemotherapy-induced Peripheral Neuropathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo capsules is the first listed.
NCT04112641 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT04112641 about?
NCT04112641 is a clinical study titled "NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy". The purpose of this randomized, double-blind, placebo-controlled, parallel group phase II trial is to determine whether nicotinamide riboside (NIAGEN®, NR) can ameliorate persistent peripheral neuropathy in cancer survivors who have completed chemotherapy with taxane or platinum-complex compounds be...
What is the current status of trial NCT04112641?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2020-02-19. Estimated completion is 2026-07-01.
What conditions does trial NCT04112641 study?
This clinical trial studies the following conditions: Chemotherapy-induced Peripheral Neuropathy.
What interventions are being tested in trial NCT04112641?
The interventions under investigation include: Placebo capsules (DRUG), Nicotinamide riboside (DRUG).
Who is sponsoring clinical trial NCT04112641?
This trial is sponsored by Donna Hammond, PhD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04112641 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chemotherapy-induced Peripheral Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04112641's enrollment target sits among peer trials
48 16th of 29 higher than 14 of 29 other Chemotherapy-induced Peripheral Neuropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chemotherapy-induced Peripheral Neuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
RECRUITING · Phase 2
-
Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
RECRUITING · Phase 2
-
A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)
ACTIVE NOT RECRUITING · Phase 2
-
PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI